IgG-Binding Peptide Linker Synthesis With Low Hydrolyzate Formation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional methods for producing IgG-binding peptides result in the generation of hydrolyzates that are difficult to separate, require high temperatures and long reaction times, and use purification methods that lead to low recovery rates, making them unsuitable for large-scale production.

Innovation Solution

The method involves reacting IgG-binding peptides with a crosslinking agent at room temperature or below in the presence of a tertiary amine with stronger basicity than pyridine, and using size exclusion chromatography for purification to reduce hydrolyzate generation and improve yield.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional methods are used to react IgG-binding peptides with crosslinking agents, then the antibody-modification linker can be produced, but hydrolyzates are generated as by-products that are difficult to separate

Engineering Contradiction:
Improvepurity of antibody-modification linkerVSAvoidhydrolyzate by-product generation
Core Design Contradiction:
Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

The patent changes the reaction parameters by using a different base (sodium hydroxide or potassium hydroxide instead of conventional bases) and controlling the reaction temperature at 50°C or below, which significantly reduces hydrolyzate generation while maintaining high yield of the antibody-modification linker

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful hydrolyzate by-product into a separable substance by changing the reaction conditions, making the by-product easier to remove through standard purification methods and thereby improving the overall purity of the final product

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If high temperature and long reaction time are used, then the reaction proceeds completely, but the production efficiency is low and it is unsuitable for large-scale preparation

Engineering Contradiction:
Improvereaction completionVSAvoidproduction efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent changes the reaction conditions by using a specific base (sodium hydroxide or potassium hydroxide) and controlling the temperature at 50°C or below, which maintains reliable reaction completion while significantly reducing the reaction time to 2 hours or less, thereby improving production efficiency for large-scale preparation

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses sodium hydroxide or potassium hydroxide as a mediator base that facilitates the reaction between the IgG-binding peptide and crosslinking agent under milder conditions, enabling the reaction to proceed efficiently at lower temperatures and shorter times while maintaining high completion rates

Inventive Principle:
Principle #24Intermediary (Mediator)

3Manufacturing precision

If reversed-phase column purification is used, then the antibody-modification linker can be purified, but the recovery rate is low

Engineering Contradiction:
Improvepurification of antibody-modification linkerVSAvoidrecovery rate
Core Design Contradiction:
Manufacturing precisionVSLoss of substance

Solution Approach 1:

The patent changes the purification approach by combining reduced hydrolyzate generation through optimized reaction conditions with size exclusion chromatography, which maintains high purification effectiveness while significantly improving the recovery rate compared to reversed-phase column methods

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach reduces hydrolyzate content while maintaining yield, allowing for high-purity and high-yield production of antibody-modification linkers in a shorter time, suitable for large-scale preparation.

Implementation Method 1

reacting a protein or peptide with a crosslinking agent in the presence of a base having a stronger basicity than pyridine, thereby binding an amino group in the protein or peptide to the crosslinking agent

Methodology Applied
Scientific EffectChemical bonding: Chemical Bonding

Implementation Method 2

using size exclusion chromatography for purification to reduce hydrolyzate generation and improve yield

Methodology Applied
Scientific EffectChromatography: Chromatography

Data Source

PatentUS20260021213A1Method for producing fc-containing molecule modifying reagent
Publication Date: 2026.01.22 NIHON MEDI PHYSICS CO LTD
  • US20260021213A1 patent drawing
  • US20260021213A1 patent drawing
  • US20260021213A1 patent drawing

AI summary

A method for producing an Fc-containing molecule modifying reagent, including reacting a protein or peptide with a crosslinking agent in the presence of a base having a stronger basicity than pyridine to bond an amino group in the protein or peptide with the crosslinking agent.